MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.22.02390

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

Krauss Daniel J, Karrison Theodore, Martinez Alvaro A, Morton Gerard, Yan Di, Bruner Deborah Watkins, Movsas Benjamin, Elshaikh Mohamed, Citrin Deborah, Hershatter Bruce, Michalski Jeff M, Efstathiou Jason Alexander, Currey Adam, Kavadi Vivek S, Cury Fabio L, Lock Michael, Raben Adam, Seaward Samantha Andrews, El-Gayed Ali, Rodgers Joseph P, Sandler Howard M

Многоцентровое исследованиеСтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

PURPOSE: It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT).

METHODS

The NRG Oncology/Radiation Therapy Oncology Group 0815 study randomly assigned 1,492 patients with stage T2b-T2c, Gleason score 7, or prostate-specific antigen (PSA) value >10 and ≤20 ng/mL to dose-escalated RT alone (arm 1) or with STAD (arm 2). STAD was 6 months of luteinizing hormone-releasing hormone agonist/antagonist therapy plus antiandrogen. RT modalities were external-beam RT alone to 79.2 Gy or external beam (45 Gy) with brachytherapy boost. The primary end point was overall survival (OS). Secondary end points included prostate cancer-specific mortality (PCSM), non-PCSM, distant metastases (DMs), PSA failure, and rates of salvage therapy.

RESULTS

Median follow-up was 6.3 years. Two hundred nineteen deaths occurred, 119 in arm 1 and 100 in arm 2. Five-year OS estimates were 90% versus 91%, respectively (hazard ratio [HR], 0.85; 95% CI, 0.65 to 1.11]; P = .22). STAD resulted in reduced PSA failure (HR, 0.52; P <.001), DM (HR, 0.25; P <.001), PCSM (HR, 0.10; P = .007), and salvage therapy use (HR, 0.62; P = .025). Other-cause deaths were not significantly different (P = .56). Acute grade ≥3 adverse events (AEs) occurred in 2% of patients in arm 1 and in 12% for arm 2 (P <.001). Cumulative incidence of late grade ≥3 AEs was 14% in arm 1 and 15% in arm 2 (P = .29).

CONCLUSION

STAD did not improve OS rates for men with IRPC treated with dose-escalated RT. Improvements in metastases rates, prostate cancer deaths, and PSA failures should be weighed against the risk of adverse events and the impact of STAD on quality of life.

Для цитирования: Krauss Daniel J, Karrison Theodore, Martinez Alvaro A, Morton Gerard, Yan Di, Bruner Deborah Watkins, Movsas Benjamin, Elshaikh Mohamed, Citrin Deborah, Hershatter Bruce, Michalski Jeff M, Efstathiou Jason Alexander, Currey Adam, Kavadi Vivek S, Cury Fabio L, Lock Michael, Raben Adam, Seaward Samantha Andrews, El-Gayed Ali, Rodgers Joseph P, Sandler Howard M. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023. DOI: 10.1200/jco.22.02390.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.